Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Junshi's PD-1 Approved for Third Indication in China, Bladder Cancer

publication date: Apr 12, 2021

Shanghai Junshi Bio announced China's NMPA approved a third indication for the company's PD-1 drug. Toripalimab is now approved as a second-line therapy for locally advanced or metastatic urothelial carcinoma in patients who failed platinum-based chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum chemotherapy. Previously, toripalimab was approved as a second-line treatment for metastatic melanoma and a third-line therapy for nasopharyngeal carcinoma. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital